Suppression of the histamine-induced wheal and flare response by fexofenadine HCl 60 mg twice daily, loratadine 10 mg once daily and placebo in healthy Japanese volunteers

References

• Bousquet J, van Cauwenberge P, Khaltaev N. Aria Workshop Group; World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108(Suppl):147–334
   Google Scholar
• Meltzer EO, Nathan RA, Selner JS, et al. Quality of life and rhinitic symptoms: results of a nationwide survey with the SF-36 and RQLQ questionnaires. J Allergy Clin Immunol 1997;99:S815–19
   Web of Science ®Google Scholar
• Ter Laak AM, Donné-Op den Kelder GM, Bast A, et al. Is there a difference in the affinity of histamine H1-receptor antagonists for CNS and peripheral receptors? An in vitro study. Eur J Pharmacol 1993;232: 199–205
   Google Scholar
• Kaliner MA. Clinical use of (H1) antihistamines in elderly patients: considerations in a polypharmaceutic patient population. Clin Geriatrics 1997;5:533–40
   Google Scholar
• Dockhorn RJ, Bergner A, Connell JT, et al. Safety and efficacy of loratadine (Sch-29851): a new non-sedating antihistamine in seasonal allergic rhinitis. Ann Allergy 1987;58:407–11
   PubMedGoogle Scholar
• Monroe EW. Relative efficacy and safety of loratadine, hydroxyzine, and placebo in chronic idiopathic urticaria and atopic dermatitis. Clin Ther 1992;14:17–21
   PubMed Web of Science ®Google Scholar
• Howarth PH, Stern MA, Roi L, et al. Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once-daily) and cetirizine in seasonal allergic rhinitis. J Allergy Clin Immunol 1999;104:927–33
   PubMed Web of Science ®Google Scholar
• van Cauwenberge P, Juniper EF. The Star Study Investigating Group. Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120 mg, loratadine 10 mg and placebo administered once daily for the treatment of seasonal allergic rhinitis. Clin Exp Allergy 2000;30: 891–9
   Google Scholar
• Casale TB, Andrade C, Qu R. Safety and efficacy of once-daily fexofenadine HCl in the treatment of autumn seasonal allergic rhinitis. Allergy Asthma Proc 1999;20:193–8
   Google Scholar
• Finn AF, Kaplan AP, Fretwell R, et al. A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria. J Allergy Clin Immunol 1999;104:1071–8
   PubMed Web of Science ®Google Scholar
• Nelson HS, Reynolds R, Mason J. Fexofenadine HCl is safe and effective for treatment of chronic idiopathic urticaria. Ann Allergy Asthma Immunol 2000;84:517–22
   PubMed Web of Science ®Google Scholar
• Bruttmann G, Charpin D, Germouty J, et al. Evaluation of the efficacy and safety of loratadine in perennial allergic rhinitis. J Allergy Clin Immunol 1989;83:411–6
   PubMed Web of Science ®Google Scholar
• Leynadier F, Duarte-Risselin C, Murrieta M. Comparative therapeutic effect and safety of mizolastine and loratadine in chronic idiopathic urticaria. URTILOR study group. Eur J Dermatol 2000;10:205–11
   PubMed Web of Science ®Google Scholar
• Simons FER, Simons KJ. Peripheral H1-blockade effect of fexofenadine. Ann Allergy Asthma Immunol 1997;79:530–2
   PubMed Web of Science ®Google Scholar
• Frossard N, Purohit A, Kovacs S. Fexofenadine is superior to loratadine and desloratadine in onset of action of histamine-induced wheal and flare inhibition. Ann Allergy Asthma Immunol 2003;90:124 [Abstract P34]
   Google Scholar
• Miyao M, Furuta M, Ozawa K, et al. Morbidity of allergic rhinitis based on the National Health Insurance records of Japan. Tohoku J Exp Med 1993;169:345–50
   PubMed Web of Science ®Google Scholar
• Bradford LD, Kirlin WG. Polymorphism of CYP2D6 in Black populations: implications for psychopharmacology. Int J Neuropsychopharmacol 1998;1:173–85
   PubMed Web of Science ®Google Scholar
• Kaliner MA, White MV, Economides A, et al. Relative potency of fexofenadine HCl 180 mg, loratadine 10 mg, and placebo using a skin test model of wheal and flare suppression. Ann Allergy Asthma Immunol 2003;90:629–34
   PubMed Web of Science ®Google Scholar
• Day JH, Briscoe MP, Welsh A, et al. Onset of action, efficacy, and safety of a single dose of fexofenadine hydrochloride for ragweed allergy using an environmental exposure unit. Ann Allergy Asthma Immunol 1997;79:533–40
   PubMed Web of Science ®Google Scholar
• Hilbert J, Radwanski E, Weglein R, et al. Pharmacokinetics and dose proportionality of loratadine. J Clin Pharmacol 1987;27:694–8
   PubMed Web of Science ®Google Scholar
• Simons FE, McMillan JL, Simons KJ. A double-blind, single-dose, cross-over comparison of cetirizine, terfenadine, loratadine, astemizole, and chlorpheniramine versus placebo: suppressive effects on histamine-induced wheals and flares during 24 hours in normal subjects. J Allergy Clin Immunol 1990;86: 540–7
   Google Scholar
• Kawashima M, Tango T, Noguchi T, et al. Addition of fexofenadine to a topical corticosteroid reduces the pruritus associated with atopic dermatitis in a 1-week, randomized, multicentre, double-blind, placebo-controlled, parallel-group study. Br J Dermatol 2003;148:1212–21
   PubMed Web of Science ®Google Scholar
• Salmun LM, Gates D, Scharf M, et al. Loratadine versus cetirizine: assessment of somnolence and motivation during the workday. Clin Ther 2000;22:573–82
   PubMed Web of Science ®Google Scholar
• Bradley CM, Nicholson AN. Studies on the central effects of the H1 antagonist, loratadine. Eur J Clin Pharmacol 1987;32:419–21
   PubMed Web of Science ®Google Scholar
• Hindmarch I, Shamsi Z. Antihistamines: models to assess sedative properties, assessment of sedation, safety and other side-effects. Clin Exp Allergy 1999;29:133–42
   PubMed Web of Science ®Google Scholar
• Hindmarch I, Shamsi Z, Stanley N, et al. A double-blind, placebo-controlled investigation of the effects of fexofenadine, loratadine and promethazine on cognitive and psychomotor function. Br J Clin Pharmacol 1999;48:200–6
   PubMed Web of Science ®Google Scholar
• Hindmarch I, Shamsi Z, Kimber S. An evaluation of the effects of high-dose fexofenadine on the central nervous system: a double-blind, placebo-controlled study in healthy volunteers. Clin Exp Allergy 2002;32:133–9
   Google Scholar